StemInov develops stem cell therapies for inflammatory diseases, focusing on septic shock and ARDS.
StemInov has raised $12.5M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
StemInov's investors include Alsace Business Angels, Finovam Gestion, Angels Santé, Les Business Angels des Grandes √âcoles, ILP - Sadepar.
StemInov is headquartered in Vandoeuvre-lès-nancy, France.
StemInov develops stem cell therapies for inflammatory diseases, focusing on septic shock and ARDS.
StemInov is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"StemInov — Funding & Investors." VCBacked, September 25, 2025, https://www.vcbacked.co/company/steminov. Accessed August 24, 2026.
VCBacked. (2025). StemInov — Funding & Investors. Retrieved August 24, 2026, from https://www.vcbacked.co/company/steminov
{{cite web |title=StemInov — Funding & Investors |url=https://www.vcbacked.co/company/steminov |website=VCBacked |access-date=August 24, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated